top of page

The Sage Group is at BIO 2025 in Boston from 16-19 June 2025! Please click here to setup a meeting!

See Latest News!

30 YEARS OF GLOBAL TRANSACTIONS FOR BIOSCIENCE COMPANIES

Search

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

bil19
Mar 3, 2022
0 min read

Updated: Jan 29, 2023

Recent Posts

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Comments

Featured Posts

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Recent Posts

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Zumutor – Licensing Opportunity for Next Generation Tumor-Directed Immunotherapeutics Harnessing the Power of NK Cells

D-PLEX100 from Polypid for Prevention of Surgical Site Infections - Seeking a US Licensing Partner

Sage Group Advises Evecxia on Licensing of EVX-101, a Novel Treatment for Depression and OCD Using Serotonin Synthesis Amplification

The Sage Group: 30 Years of Successful Bioscience Transactions

Coagulant’s CT-001 - An Opportunity To License A Novel Factor VIIa with Orphan Drug Designation for the Treatment of Severe Postpartum Hemorrhage (sPPH)

Archive

Search By Tags

Follow Us

bottom of page